Glucotrack has announced its participation in the EU-funded FORGETDIABETES initiative, aiming to develop a long-term automated insulin delivery system that requires no patient intervention.
The New Jersey-based company will contribute its investigational continuous blood glucose monitor (CBGM), which delivers real-time glucose data to guide insulin delivery decisions. This marks a step toward integrating Glucotrack’s implantable CBGM technology into a fully automated bionic pancreas solution.
Supported by the Horizon 2020 program, the project combines basic research and product development to enable optimal, hands-free glucose control for diabetic patients.
Follow MEDWIRE.AI for updates on diabetes tech innovation.
